Completed PHASE3 INTERVENTIONAL 2-arm NCT03911466

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (MOMs-CMA)

NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Drug Abuse Drug Abuse in Pregnancy Drug Addiction Neonatal Abstinence Syndrome Neonatal Opioid Withdrawal Syndrome Opioid-Related Disorders Pregnancy Related Substance Abuse

Interventions Buprenorphine Injection Buprenorphine Sublingual Product

Updated 21 times since 2019 Last updated: Feb 19, 2025 Started: Jul 21, 2020 Primary completion: Nov 6, 2024 Completion: Nov 6, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Drug Abuse and Drug Abuse in Pregnancy and is currently completed. National Institute on Drug Abuse (NIDA) leads this study, which shows 21 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

21 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Dec 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Dec 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 16 earlier versions

Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jun 2023 [monthly]

Recruiting PHASE3
Mar 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Mar 2022 [monthly]

Recruiting PHASE3
Sep 2021 — Dec 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Sep 2020 — Nov 2020 [monthly]

Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE3
Mar 2020 — Jul 2020 [monthly]

Not Yet Recruiting PHASE3
Oct 2019 — Mar 2020 [monthly]

Not Yet Recruiting PHASE3
Jun 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE3
May 2019 — Jun 2019 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)
T. John Winhusen, PhD
The Emmes Company, LLC

Data source: University of Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Boston, United States , Charleston, United States , Cincinnati, United States , Huntington, United States , Jacksonville, United States , Nashville, United States , Pittsburgh, United States , Portland, United States , Salt Lake City, United States and 1 more location